Echinocandin to fluconazole step-down therapy in critically ill patients with invasive, susceptible Candida albicans infections

Mycoses

Volumn 59, Issue 3, 2016, Pages 179-185

  Van Der Geest, Patrick J ^a   Rijnders, Bart J A ^a   Vonk, Alieke G ^a   Groeneveld, A B Johan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

C. albicans; Candidaemia; Echinocandin; Fluconazole; Invasive candidiasis

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPEPTIDE;

ADULT; AGED; ARTICLE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFECTION SENSITIVITY; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; CANDIDIASIS, INVASIVE; CLASSIFICATION; CRITICAL ILLNESS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDIASIS, INVASIVE; CRITICAL ILLNESS; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HUMANS; INTENSIVE CARE UNITS; LIPOPEPTIDES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES;

EID: 84958603438     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12450     Document Type: Article

References (30)

1. Kett DH, Azoulay E, Echeverria PM, Vincent JL. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2001; 39: 665-70.
2. Chow JK, Golan Y, Ruthazer R et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008; 46: 1206-13.
3. Guery BP, Arendrup MC, Auzinger G et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis. Intensive Care Med 2009; 35: 55-62.
4. Leroy O, Gangneux JP, Montravers P et al.; AmarCand Study Group. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009; 37: 1612-8.
5. Eggimann P, Bille J, Marchetti O. Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care 2011; 1: 37.
6. Glöckner A. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature. Eur J Med Res 2011; 16: 167-79.
7. Colombo AL, Guimaraes T, Sukienik T et al. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med 2014; 40: 1489-98.
8. Dimopoulos G, Ntziora F, Rachiotis G, Armaganidis A, Falagas ME. Candida albicans versus non-candida albicans intensive care unit-acquired bloodstream infection: differences in risk factors and outcome. Anesth Analg 2008; 106: 523-9.
9. Prowle JR, Echeverri JE, Ligabo EV et al. Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality. Crit Care 2011; 15: R100.
10. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
11. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi institutional study. Clin Infect Dis 2006; 43: 25-31.
12. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
13. Cornely OA, Bassetti M, Calandra T et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Inf 2012; 18: 19-37.
14. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
15. Kett DH, Shorr AF, Reboli AC, Reisman AL, Biswas P, Schlamm HT. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Crit Care 2009; 15: R253.
16. Reboli AC, Shorr AF, Rotstein C et al. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Inf Dis 2011; 11: 261.
17. Wade RL, Chaudhari P, Campbell RS et al. Treatment of candidemia with echinocandins: data on hospital resource use from a real world setting. J Med Econ 2012; 15: 1130-8.
18. Bassetti M, Marchetti M, Chakrabarti A et al. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med 2013; 39: 2092-106.
19. Bal AM, Shankland GS, Scott G, Imtiaz T, Macaulay R, McGill M. Antifungal step-down therapy based on hospital intravenous to oral switch policy and susceptibility testing in adult patients with candidaemia: a single centre experience. Int J Clin Pract 2014; 68: 20-27.
20. Vazquez J, Reboli AC, Pappas PG et al. Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial. BMC Inf Dis 2014; 14: 97.
21. Clinical and Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: 4th Informational Supplement. Wayne, PA: CLSI, 2012.
22. Oude Lashof AML, Janssen JJWM, Meis JFGM et al. SWAB- richtlijn voor de behandeling van invasieve schimmelinfecties 2013. NVMM; 18: 13-17.
23. León C, Ruiz-Santana S, Saavedra P et al. Usefulness of the 'Candida score' for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009; 37: 1624-33.
24. Maubon D, Garnaud C, Calandra T, Sanglard D, Cornet M. Resistance of Candida spp. To antifungal drugs in the ICU: where are we now? Intensive Care Med 2014; 40: 1241-55.
25. Bally S, Leroy O, Montravers P et al. Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data. Intensive Care Med 2015; 41: 1931-40.
26. Wilke MH. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs - review of the literature. Eur J Med Res 2011; 16: 180-6.
27. Masterton RG, Casamayor M, Musingarimi P et al. De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections. J Med Econ 2013; 16: 1344-56.
28. Alexander BD, Johnson MD, Pfeiffer CD et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013; 56: 1724-32.
29. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010; 48: 2373-80.
30. Bassetti M, Ansaldi F, Nicolini L et al. Incidence of candidemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother 2009; 64: 625-9.